Myeloid Neoplasms With MyelofibrosisPhase 1/2JAK-PeriMFNCT07883382
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 1/2 study testing gecacitinib Hydrochloride Tablets in people with Myeloid Neoplasms With Myelofibrosis, run by Ruijin Hospital at 1 site in China.
Trial summary
This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).Approximately 10… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myeloid Neoplasms With Myelofibrosis
- What is being tested?
- gecacitinib Hydrochloride Tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteChina
- Study dates
- 15 Oct 2026to 30 Sep 2029
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must voluntarily sign the informed consent form, be aged ≥18 years at the time of informed consent, and may be of either sex.
- Diagnosed with myeloid neoplasms according to 2022 WHO diagnostic criteria
- Bone marrow fibrosis grade ≥2 according to 2016 WHO myelofibrosis grading criteria
- Undergoing first allogeneic hematopoietic stem cell transplantation
- ECOG performance status: 0-2
- Able to swallow tablets
- Able to comply with study procedures and follow-up requirements
Who cannot join
- Currently receiving JAK inhibitors other than gecacitinib at screening (patients who have switched from other JAK inhibitors to gecacitinib before screening are eligible)
- Prior allogeneic hematopoietic stem cell transplantation or organ transplantation
- Uncontrolled severe infection, shock, severe organ failure, or any other condition that would preclude tolerance of the study treatment at enrollment.
- Any significant clinical or laboratory abnormality that may affect safety evaluation, including:
- Uncontrolled diabetes (fasting blood glucose >13.9 mmol/L)
- Uncontrolled hypertension despite ≥2 antihypertensive drugs (SBP ≥160 mmHg or DBP ≥100 mmHg)
Show all 22Show fewer
- Peripheral neuropathy (NCI-CTC AE v5.0 grade ≥2)
- Serum creatinine >1.5×ULN
- ALT or AST >2.5×ULN; DBIL or TBIL >2.0×ULN
- Any of the following within 6 months before screening: NYHA class III-IV congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident, or pulmonary embolism; arrhythmia requiring treatment; or QTcB >480 ms.
- Known active gastrointestinal ulcer at screening, or a history of gastrectomy or intestinal resection that may affect drug absorption.
- Major surgery within 4 weeks before screening without full recovery
- Known HIV infection and/or AIDS
- History of tuberculosis infection
- Epilepsy or use of psychotropic/sedative drugs at screening
- Pregnant or breastfeeding women; patients unable to use effective contraception throughout the study period
- Any other comorbidity that may affect the study or prior malignancy
- Treatment with anticoagulant or antiplatelet drugs (except low molecular weight heparin)
- Other severe conditions that, in the investigator's judgment, may affect patient safety or compliance
- Known hypersensitivity to gecacitinib hydrochloride, drugs of the same class, or any excipients
- Participation in other investigational drug or medical device clinical trials within 3 months before screening
- Any comorbidity or prior malignancy that, in the investigator's judgment, may affect study participation, safety evaluation, or interpretation of study results.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
No. 197, Ruijin Second Road, Shanghai
Shanghai
Zilu Zhang, PhD, 021-64370045, zzl12402@rjh.com.cn
About this study
Official title: An Exploratory Study of Gecacitinib in the Peri-Transplant Period for Patients With Myeloid Neoplasms and Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).Approximately 10 eligible patients will receive oral gecacitinib starting 13 weeks before transplantation. Treatment will continue through the peri-transplant period and for up to 24 weeks after hematopoietic reconstitution. The primary endpoint is the engraftment rate at day +28 post-transplant. Secondary endpoints include poor graft function rate, grade III-IV acute GVHD rate, overall survival, infection rate, and bone marrow fibrosis grade changes.
Read the detailed description
Background: Myelofibrosis (MF) and other myeloid neoplasms with myelofibrosis are associated with significant clinical symptoms that can adversely affect the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT). JAK inhibitors are recommended as bridging therapy before transplantation in MF patients with high symptom burden, but the optimal peri-transplant management strategy remains an area of active investigation.
Gecacitinib is a next-generation JAK inhibitor that has demonstrated superior efficacy and a better hematologic safety profile than ruxolitinib in previous studies. In frontline patients with MF, treatment with gecacitinib resulted in a spleen volume response rate (SVR35) of 64.8%, significantly higher than ruxolitinib (27%), with a lower incidence of anemia than that observed with ruxolitinib (36.6% vs. 50.8%). Preclinical studies have also shown that gecacitinib can prolong survival and alleviate GVHD in a huPBMC-NCG mouse model.
Study Design: This is a single-arm, single-center, exploratory clinical study. Approximately 10 patients with myeloid neoplasms and bone marrow fibrosis of grade ≥2 who are scheduled to undergo their first allo-HSCT will be enrolled.
Intervention: gecacitinib will be administered orally starting 13 weeks before transplantation. The starting dose is determined by baseline platelet count: 100 mg BID for platelets ≥50×10^9/L, or 50 mg BID for platelets <50×10^9/L. The dose will be reduced to 50 mg BID beginning 1 week before transplantation (day -7) and will be maintained at this dose during conditioning and transplantation, then increased to 100 mg BID after hematopoietic reconstitution (PLT ≥50×10^9/L and ANC ≥0.5×10^9/L), maintained for 12 weeks, then tapered to 50 mg BID for another 12 weeks before discontinuation.
Primary Outcome: Engraftment rate at day +28 post-transplant (defined as neutrophil count >0.5×10^9/L for 3 consecutive days and platelet count >20×10^9/L for 7 consecutive days without platelet transfusion support).
Follow-up: Patients will be followed for 2 years after transplantation or until death or loss to follow-up, whichever occurs first.
- Conditions
- Myeloid Neoplasms With Myelofibrosis
- Being tested
- gecacitinib Hydrochloride Tablets
- Keywords
- Myelofibrosis, Myeloid Neoplasms, Allogeneic Hematopoietic Stem Cell Transplantation, JAK Inhibitor, gecacitinib
- Medical subject headings
- Primary Myelofibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
gecacitinib Hydrochloride TabletsDrug
gecacitinib is administered orally, starting 13 weeks before allo-HSCT. Starting dose is based on baseline platelet count: 100 mg twice daily (BID) if platelets ≥50×10^9/L, or 50 mg BID if platelets <50×10^9/L.The dose will be reduced to 50 mg BID beginning on day -7 (1 week before transplantation) and maintained at this dose during conditioning and transplantation. After hematopoietic reconstitution (PLT ≥50×10^9/L and ANC ≥0.5×10^9/L), the dose is increased to 100 mg BID for 12 weeks, then tapered to 50 mg BID for another 12 weeks before discontinuation.
Dose adjustments are made based on adverse events and hematologic parameters, with a maximum dose of 100 mg BID and minimum of 50 mg once daily (QD).
| Study group | Role | What they receive |
|---|---|---|
| Experimental: gecacitinib Peri-Transplant | Experimental | gecacitinib is administered orally, starting 13 weeks before allo-HSCT. Starting dose is based on baseline platelet count: 100 mg twice daily (BID) if platelets ≥50×10^9/L, or 50 mg BID if platelets <50×10^9/L.The dose will be reduced to 50 mg BID beginning on day -7 (1 week before transplantation) and maintained at this dose during conditioning and transplantation. After hematopoietic reconstitution (PLT ≥50×10^9/L and ANC ≥0.5×10^9/L), the dose is increased to 100 mg BID for 12 weeks, then tapered to 50 mg BID for another 12 weeks before discontinuation. Receives: Drug: gecacitinib Hydrochloride Tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Engraftment Rate at Day +28 Post-Transplant
Percentage of patients who achieve both neutrophil engraftment (ANC >0.5×10^9/L for 3 consecutive days) and platelet engraftment (PLT >20×10^9/L for 7 consecutive days without platelet transfusion) by day +28 after transplantation.
Measured: Day +28 post-transplant
Secondary outcomes (6)
Incidence of Poor Graft Function (PGF) at Day +180
PGF is defined as persistent cytopenia(s), including ANC <0.5×10^9/L, PLT <20×10^9/L or platelet transfusion dependence, and/or Hb <70 g/L or red blood cell transfusion dependence, lasting for at least 2 weeks after initial donor engraftment, with hypoplastic marrow, full donor chimerism, and exclusion of relapse, rejection, severe GVHD, active infection, drug-related myelosuppression, or other identifiable causes.
Measured: Day +180 post-transplant
Incidence of Grade III-IV Acute Graft-Versus-Host Disease (aGVHD) at Day +180
Percentage of patients developing grade III-IV acute GVHD within 180 days after transplantation, graded according to standard criteria.
Measured: Day +180 post-transplant
Overall Survival (OS) at 1 Year Post-Transplant
Overall survival is defined as the time from transplantation to death from any cause. The 1-year overall survival rate is the percentage of patients alive 1 year after transplantation.
Measured: 1 year post-transplant
Incidence of Severe Infections Within 180 Days Post-Transplant
Percentage of patients experiencing grade ≥3 infections within 180 days after transplantation.
Measured: Within 180 days post-transplant
Bone Marrow Fibrosis Grade Changes at Day +90 and Day +180
Proportion of patients with decreased, increased, or stable bone marrow fibrosis grade at day +90 and day +180 compared to baseline, assessed according to the 2016 WHO myelofibrosis grading criteria.
Measured: Day +90 and Day +180 post-transplant
Safety and Tolerability - Adverse Events
Incidence and severity of treatment-emergent adverse events (TEAEs), graded according to NCI-CTCAE v5.0 criteria.
Measured: From start of study drug until 28 days after last dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2026
- Study start15 Oct 2026 (estimated)
- Primary completion28 Oct 2028 (estimated)
- Study completion30 Sep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myeloid Neoplasms With MyelofibrosisStudies of the same condition, open and under way.
- More trials run by Ruijin HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Drug: gecacitinib Hydrochloride Tablets
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ruijin Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hu Xiaoxia, Ruijin Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07883382
- Sponsor's protocol ID
- 20260918051934228
- Acronym
- JAK-PeriMF
- Status last verified
- Oct 2026
- First submitted
- 13 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because the informed consent obtained from participants does not cover external data sharing. Given the sensitive nature of the data and the small study population, sharing de-identified participant-level data may also pose a risk of re-identification. Aggregate results will be reported in study publications.
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Exploratory Study of Gecacitinib in the Peri-Transplant Period for Patients With Myeloid Neoplasms and Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- ClinicalTrials.gov ID
- NCT07883382
- Acronym / sponsor ID
- JAK-PeriMF / 20260918051934228
- Conditions
- Myeloid Neoplasms With Myelofibrosis
- Keywords
- Myelofibrosis, Myeloid Neoplasms, Allogeneic Hematopoietic Stem Cell Transplantation, JAK Inhibitor, gecacitinib
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Ruijin HospitalUniversity, hospital or other
- Study start
- 15 Oct 2026 (estimated)
- Primary completion
- 28 Oct 2028 (estimated)
- Study completion
- 30 Sep 2029 (estimated)
- First posted
- 20 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).Approximately 10 eligible patients will receive oral gecacitinib starting 13 weeks before transplantation. Treatment will continue through the peri-transplant period and for up to 24 weeks after hematopoietic reconstitution. The primary endpoint is the engraftment rate at day +28 post-transplant. Secondary endpoints include poor graft function rate, grade III-IV acute GVHD rate, overall survival, infection rate, and bone marrow fibrosis grade changes.
Detailed description
Background: Myelofibrosis (MF) and other myeloid neoplasms with myelofibrosis are associated with significant clinical symptoms that can adversely affect the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT). JAK inhibitors are recommended as bridging therapy before transplantation in MF patients with high symptom burden, but the optimal peri-transplant management strategy remains an area of active investigation.
Gecacitinib is a next-generation JAK inhibitor that has demonstrated superior efficacy and a better hematologic safety profile than ruxolitinib in previous studies. In frontline patients with MF, treatment with gecacitinib resulted in a spleen volume response rate (SVR35) of 64.8%, significantly higher than ruxolitinib (27%), with a lower incidence of anemia than that observed with ruxolitinib (36.6% vs. 50.8%). Preclinical studies have also shown that gecacitinib can prolong survival and alleviate GVHD in a huPBMC-NCG mouse model.
Study Design: This is a single-arm, single-center, exploratory clinical study. Approximately 10 patients with myeloid neoplasms and bone marrow fibrosis of grade ≥2 who are scheduled to undergo their first allo-HSCT will be enrolled.
Intervention: gecacitinib will be administered orally starting 13 weeks before transplantation. The starting dose is determined by baseline platelet count: 100 mg BID for platelets ≥50×10^9/L, or 50 mg BID for platelets <50×10^9/L. The dose will be reduced to 50 mg BID beginning 1 week before transplantation (day -7) and will be maintained at this dose during conditioning and transplantation, then increased to 100 mg BID after hematopoietic reconstitution (PLT ≥50×10^9/L and ANC ≥0.5×10^9/L), maintained for 12 weeks, then tapered to 50 mg BID for another 12 weeks before discontinuation.
Primary Outcome: Engraftment rate at day +28 post-transplant (defined as neutrophil count >0.5×10^9/L for 3 consecutive days and platelet count >20×10^9/L for 7 consecutive days without platelet transfusion support).
Follow-up: Patients will be followed for 2 years after transplantation or until death or loss to follow-up, whichever occurs first.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Drug: gecacitinib Hydrochloride Tablets
| Arm | Type | Receives |
|---|---|---|
| Experimental: gecacitinib Peri-Transplant | Experimental | Drug: gecacitinib Hydrochloride Tabletsgecacitinib is administered orally, starting 13 weeks before allo-HSCT. Starting dose is based on baseline platelet count: 100 mg twice daily (BID) if platelets ≥50×10^9/L, or 50 mg BID if platelets <50×10^9/L.The dose will be reduced to 50 mg BID beginning on day -7 (1 week before transplantation) and maintained at this dose during conditioning and transplantation. After hematopoietic reconstitution (PLT ≥50×10^9/L and ANC ≥0.5×10^9/L), the dose is increased to 100 mg BID for 12 weeks, then tapered to 50 mg BID for another 12 weeks before discontinuation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients must voluntarily sign the informed consent form, be aged ≥18 years at the time of informed consent, and may be of either sex.
- Diagnosed with myeloid neoplasms according to 2022 WHO diagnostic criteria
- Bone marrow fibrosis grade ≥2 according to 2016 WHO myelofibrosis grading criteria
- Undergoing first allogeneic hematopoietic stem cell transplantation
- ECOG performance status: 0-2
Key exclusion criteria (22 listed)
- Currently receiving JAK inhibitors other than gecacitinib at screening (patients who have switched from other JAK inhibitors to gecacitinib before screening are eligible)
- Prior allogeneic hematopoietic stem cell transplantation or organ transplantation
- Uncontrolled severe infection, shock, severe organ failure, or any other condition that would preclude tolerance of the study treatment at enrollment.
- Any significant clinical or laboratory abnormality that may affect safety evaluation, including:
- Any of the following within 6 months before screening: NYHA class III-IV congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident, or pulmonary embolism; arrhythmia requiring treatment; or QTcB >480 ms.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| gecacitinib Hydrochloride Tabletsgecacitinib is administered orally, starting 13 weeks before allo-HSCT. Starting dose is based on baseline platelet count: 100 mg twice daily (BID) if platelets ≥50×10^9/L, or 50 mg BID if platelets <50×10^9/L.The dose will be reduced to 50 mg BID beginning on day -7 (1 week before transplantation) and maintained at this dose during conditioning and transplantation. After hematopoietic reconstitution (PLT ≥50×10^9/L and ANC ≥0.5×10^9/L), the dose is increased to 100 mg BID for 12 weeks, then tapered to 50 mg BID for another 12 weeks before discontinuation. Dose adjustments are made based on adverse events and hematologic parameters, with a maximum dose of 100 mg BID and minimum of 50 mg once daily (QD). | Drug | Experimental: gecacitinib Peri-Transplant |
Primary outcome
Engraftment Rate at Day +28 Post-Transplant
Time frame: Day +28 post-transplant
Percentage of patients who achieve both neutrophil engraftment (ANC >0.5×10^9/L for 3 consecutive days) and platelet engraftment (PLT >20×10^9/L for 7 consecutive days without platelet transfusion) by day +28 after transplantation.
6 secondary outcomes
Incidence of Poor Graft Function (PGF) at Day +180
Time frame: Day +180 post-transplant
Incidence of Grade III-IV Acute Graft-Versus-Host Disease (aGVHD) at Day +180
Time frame: Day +180 post-transplant
Overall Survival (OS) at 1 Year Post-Transplant
Time frame: 1 year post-transplant
Incidence of Severe Infections Within 180 Days Post-Transplant
Time frame: Within 180 days post-transplant
Bone Marrow Fibrosis Grade Changes at Day +90 and Day +180
Time frame: Day +90 and Day +180 post-transplant
Safety and Tolerability - Adverse Events
Time frame: From start of study drug until 28 days after last dose
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because the informed consent obtained from participants does not cover external data sharing. Given the sensitive nature of the data and the small study population, sharing de-identified participant-level data may also pose a risk of re-identification. Aggregate results will be reported in study publications.
Related trials for Myeloid Neoplasms With Myelofibrosis
Not yet recruitingPhase 1
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation
RecruitingObservational study
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Chronic Myeloproliferative Disorders, Leukemia
Active, not recruitingObservational study
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
RecruitingPhase 1
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
AML, Acute Myeloid Leukemia
RecruitingPhase 1
Therapeutic RSK1 Targeting in Myeloid Malignancies
Myeloid Malignancy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing gecacitinib Hydrochloride Tablets in people with Myeloid Neoplasms With Myelofibrosis, run by Ruijin Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zilu Zhang, PhD (021-64370045, zzl12402@rjh.com.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Engraftment Rate at Day +28 Post-Transplant (time frame: Day +28 post-transplant). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.